Current disease status-First occurrence of the cancer - Page 13 of 59 Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the cancer Posts on Medivizor

Evaluating cabazitaxel in patients with metastatic castration-resistant prostate cancer

Evaluating cabazitaxel in patients with metastatic castration-resistant prostate cancer

Posted by on Sep 6, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the effectiveness of cabazitaxel used for patients with metastatic castration-resistant prostate cancer. This study found that patients treated with cabazitaxel had maintained or improved quality of life and pain control. Some background One treatment option for prostate cancer is androgen deprivation...

Read More

Looking for patients with triple negative breast cancer to test atezolizumab

Posted by on Aug 31, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of chemotherapy and atezolizumab (Tecentriq), given before surgery, for triple negative breast cancer. The main outcomes to be measured will be response in the breast tissue and lymph nodes and survival. The details Triple negative breast cancer is not dependent on the HER2 receptors or...

Read More

Comparing daily versus weekly imaging checks in radiation therapy for prostate cancer

Posted by on Aug 26, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the best timing of treatment verification imaging used in radiation therapy for patients with prostate cancer. This study found that patients undergoing daily imaging had less risk of their cancer returning and had reduced rectal side-effects. Some background One main treatment option for prostate cancer...

Read More

Should men with castration-resistant metastatic prostate cancer receive further hormone therapy?

Should men with castration-resistant metastatic prostate cancer receive further hormone therapy?

Posted by on Aug 21, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...

Read More

Everolimus and exemstane for treatment of HR+/HER2- advanced or metastatic breast cancer

Everolimus and exemstane for treatment of HR+/HER2- advanced or metastatic breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

In a nutshell This study looked at the effectiveness and safety of a combination of two cancer drugs, everolimus (Afinitor) and exemestane (Aromasin), in women after menopause with advanced breast cancer. The authors found that these drugs were safe and effective in the treatment of these women. Some background Breast cancer is...

Read More

Combining therapies to treat advanced NSCLC

Posted by on Jul 14, 2018 in Lung cancer | 0 comments

In a nutshell This trial examined the effectiveness of combining the targeted therapy drug pembrolizumab (Keytruda) with chemotherapy at treating certain types of advanced non-small-cell lung cancer. The trial concluded that this combination is more beneficial than chemotherapy alone for treating this subset of patients. Some background PD-1...

Read More

Oxaliplatin based treatments as adjuvant chemotherapy treatment in colon cancer patients

Oxaliplatin based treatments as adjuvant chemotherapy treatment in colon cancer patients

Posted by on Jul 14, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of a 3-month oxaliplatin-based chemotherapy treatment after surgery in patients with stage 3 colon cancer. Researchers suggested 6-months of treatment is associated with better outcomes. Some background The current standard treatment for stage 3 colon cancer patients is surgery followed by...

Read More